Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/139386| Title: | Drug design and optimisation of the fibroblast growth factor receptor type 4 (FGFR4) |
| Authors: | Buhagiar, Martina |
| Keywords: | Drugs -- Design Pharmaceutical chemistry Fibroblast growth factors -- Receptors Protein kinases -- Inhibitors Antineoplastic agents -- Development |
| Issue Date: | 2025 |
| Publisher: | University of Malta. Department of Pharmacy |
| Citation: | Buhagiar, M. (2025). Drug design and optimisation of the fibroblast growth factor receptor type 4 (FGFR4). Poster session presented at the 83rd FIP World Congress of Pharmacy and Pharmaceutical Sciences, Copenhagen. |
| Abstract: | Introduction: FGFR4 and its ligand FGF19 drive oncogenic proliferation and contribute
to chemotherapy resistance in several cancer types. Selective FGFR4
inhibition significantly improves tumour prognosis and reduces the
associated high mortality rates.
Infigratinib, a potent FGFR inhibitor, has the potential to silence FGFR4
signalling pathway and is the lead molecule of this study. Aims: • To identify and design high affinity, drug-like FGFR4 inhibitors by probing the FGFR4 ligand binding pocket (FGF4_LBP) at an atomic level. • To use infigratinib (Figure 1), as the lead molecule to design Lipinski- Rule-compliant molecular analogues through virtual screening (VS) and de novo drug design. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/139386 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Drug design and optimisation of the fibroblast growth factor receptor type 4 FGFR4 2025.pdf | 787.95 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.